Inverse Psoriasis: Intertriginous Disease, Diagnosis, and Management Challenges

Clinical Overview

Inverse psoriasis, also termed flexural or intertriginous psoriasis, presents as sharply demarcated erythematous patches and plaques affecting skin folds and intertriginous regions (axillae, groin, submammary, gluteal cleft, umbilicus) with characteristic minimal or absent scaling. This variant accounts for 3-7% of psoriasis cases but often coexists with plaque psoriasis in 73% of affected individuals. The moist intertriginous environment produces clinically distinct morphology and therapeutic challenges compared to extensor variants.

Epidemiology

Inverse psoriasis typically manifests in adults aged 40-60 years, with female predominance (female-to-male ratio 2.3:1). Obesity is significant risk factor (odds ratio 2.8), with increased prevalence in patients with BMI >30. Prevalence 2-5 times higher in immunosuppressed populations (HIV, transplant recipients). HLA-Cw6 prevalence 40-50% (lower than plaque variant), suggesting distinct genetic associations. Secondary infection with Candida albicans occurs in 35-40% due to warm, humid microenvironment. Comorbid atopic dermatitis develops in 20%, further compromising skin barrier function.

Pathophysiology

Inverse psoriasis shares fundamental Th17/IL-17-driven pathogenesis with plaque disease; however, intertriginous location produces unique inflammatory milieu. High humidity and occlusion promote increased transepidermal water loss, compromising skin barrier. Enhanced skin flora colonization, particularly Candida species, contributes inflammatory mediators triggering innate immunity through dectin-1 and TLR signaling. TNF-alpha and IL-17A activate keratinocytes and resident dermal macrophages. Friction and maceration create ideal environment for secondary bacterial (Staphylococcus aureus, beta-hemolytic streptococci) colonization perpetuating inflammation. Reduced sebaceous gland density and eccrine sweat gland hyperactivity in intertriginous areas increase microbial proliferation and inflammatory mediator concentration.

Clinical Presentation

Inverse psoriasis presents as sharply demarcated erythematous patches/plaques in axillae, inguinal folds, submammary areas, and gluteal cleft, characteristically WITHOUT significant scaling. Minimal or fine scale distinguishes from plaque variant. Lesions are warm, moist, and prone to erosion with minimal trauma. Pruritus intense in 80%, pain reported in 60% due to fissuring and secondary infection. Mal-odor develops with Candida superinfection. Nail involvement absent. Mucosal involvement rare. Seasonal variation less pronounced than plaque disease.

Diagnosis

Diagnosis primarily clinical, though challenging due to lack of scale mimicking dermatitis or intertrigo. Dermoscopy shows acanthosis without characteristic parakeratosis of plaque psoriasis. Histopathology reveals psoriasiform acanthosis with regular rete ridge elongation, but parakeratosis may be absent or minimal. Candida superinfection demonstrates PAS-positive septate hyphae and budding yeasts on histology. Consider lesional culture or KOH preparation to exclude/confirm candidiasis (positive in 35-40%). Viral culture excludes HSV if vesiculation present. Distinguish from atopic dermatitis (lichenification, eczematous morphology, prurigo nodosus), irritant contact dermatitis (exposure history), seborrheic dermatitis (scalp/face predominance), and erythrasma (fine scale, coral-red Wood lamp fluorescence).

Treatment Algorithm

First-Line Topical Therapy: Moderate-to-potent topical corticosteroids remain first-line for limited-area disease (<10 cm² involvement per site). Hydrocortisone 1-2.5% cream twice daily for face/intertriginous areas (lower potency due to occlusion and skin atrophy risk). Betamethasone valerate 0.1% cream or triamcinolone 0.1% cream twice daily for larger areas. Limit duration to 2-4 weeks due to skin atrophy risk in thin-skinned intertriginous areas. Ointment vehicles preferred over creams due to barrier enhancement; however, occlusion may worsen infection risk.

Alternative Topical Agents: Calcineurin inhibitors (tacrolimus 0.1% ointment, pimecrolimus 1% cream) twice daily are preferred steroid-sparing agents, particularly in face, neck, and skin folds. Lack atrophy risk, permitting long-term use. Response takes 2-4 weeks. Topical vitamin D analogs (calcipotriol 50mcg/g) less effective in inverse disease due to poor penetration in moist areas and tendency toward irritation.

Antifungal Therapy: If Candida superinfection confirmed or suspected (pruritus, maceration, erythema, mal-odor), combine with topical azoles: miconazole 2% or clotrimazole 1% cream twice daily until clear, then taper. Oral fluconazole 150mg once weekly x 4 weeks for recurrent/severe candidiasis. Prophylactic fluconazole 150mg monthly effective in immunosuppressed patients with recurrent candidiasis.

Systemic Therapy (Moderate-Severe Inverse Psoriasis): For extensive intertriginous involvement (>50 cm² cumulative), systemic therapy required. Methotrexate 7.5-20mg weekly shows response in 75% within 8-12 weeks. Acitretin 25-50mg daily effective but less commonly used due to teratogenicity. Cyclosporine 3-5 mg/kg/day provides rapid response (2-3 weeks) but requires renal/BP monitoring. Biologic agents: TNF-inhibitors (etanercept 50mg SC twice weekly, adalimumab 40mg SC every other week) or IL-17 inhibitors (secukinumab 300mg SC weekly x 4, then monthly) show superior response (PASI-90 achievement 75-85% vs. 60% methotrexate alone).

Supportive Care: Weight reduction 5-10% substantially improves disease (PASI reduction 40%). Moisture-wicking textiles reduce maceration. Keep areas dry with absorbent cloth/powder. Avoid friction; use properly fitting undergarments. Discontinue irritants (soap, harsh cleansers). Weekly topical antifungal prophylaxis effective in recurrent candidiasis (miconazole powder or tolnaftate 1% powder).

Prognosis

Inverse psoriasis significantly impairs quality of life due to pruritus and discomfort. However, systemic therapy response rates comparable to plaque disease (70-85% achieving PASI-75 with biologics). Spontaneous remission rare (<5% off-therapy). Candida superinfection recurs in 40% within 6 months without prophylaxis. Biologic therapy permits long-term disease control with maintenance therapy; 20% demonstrate durable remission allowing treatment intervals to extend to every 6-8 weeks.

When to See a Dermatologist

Refer for: extensive intertriginous involvement, recurrent candidiasis, topical therapy failure, systemic therapy consideration, or diagnostic uncertainty. Dermatologists establish treatment hierarchy (candidiasis first, then psoriasis-directed therapy) and monitor for complications including secondary bacterial infection and skin atrophy from potent topical steroids.

Frequently Asked Questions

Q: Why is my psoriasis worse in skin folds?
A: Intertriginous areas are warm, moist, and occluded—creating ideal environment for Candida and bacterial overgrowth, which trigger/perpetuate inflammation. Occlusion increases topical medication penetration (enhancing efficacy and toxicity). These areas are also subject to friction, further damaging the compromised skin barrier.

Q: Is this a yeast infection?
A: Inverse psoriasis is not a yeast infection, but 35-40% of cases develop secondary Candida superinfection due to the warm, moist intertriginous environment. Testing (KOH prep, culture) distinguishes Candida-induced versus psoriasis-predominant inflammation, guiding treatment.

Q: Can topical steroids cause problems in skin folds?
A: Yes. Intertriginous areas have thin stratum corneum with high occlusion due to skin-to-skin contact, dramatically increasing topical steroid absorption. Prolonged potent steroid use risks skin atrophy, striae, and systemic absorption. Calcineurin inhibitors (tacrolimus, pimecrolimus) preferred for long-term fold therapy.

Q: Will losing weight help?
A: Yes substantially. Weight loss of 5-10% produces 40% PASI reduction. Reduced skinfold depth and reduced friction/occlusion both contribute. Weight reduction also decreases visceral adiposity-derived inflammatory mediators (IL-6, TNF-alpha, leptin).

References